AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (NCT07215585)
A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.
Who can join: Review the eligibility criteria below.
Location: Research Site — Clayton
Age range: 65 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- Research Site — Clayton,
- Research Site — Macquarie University,
- Research Site — Melbourne,
- Research Site — Nedlands,
- Research Site — Waratah,
- Research Site — Antwerp,
- Research Site — Brussels,
- Research Site — Ghent,
- Research Site — Leuven,
- Research Site — Roeselare,
- Research Site — Yvoir,
- Research Site — Porto Alegre,
- Research Site — São Paulo,
- Research Site — Calgary, Alberta
- Research Site — Victoria, British Columbia
- Research Site — Hamilton, Ontario
- Research Site — Ottawa, Ontario
- Research Site — Beijing,
- Research Site — Changchun,
- Research Site — Chengdu,
- Research Site — Chongqing,
- Research Site — Fuzhou,
- Research Site — Guangzhou,
- Research Site — Guangzhou,
- Research Site — Haikou,
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Large B-cell Lymphoma
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Anchorage, Alaska
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma — Mobile, Alabama
- Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma — St Louis, Missouri
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas — Cleveland, Ohio
- Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Houston, Texas
- CAR-T Followed by Bispecific Antibodies — Omaha, Nebraska
Explore by condition: All Large B-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.